Safe and effective conversion of persistent atrial fibrillation to sinus rhythm by intravenous AZD7009

Heart Rhythm

Volumn 3, Issue 11, 2006, Pages 1321-1331

  Crijns, Harry J ^a   Van Gelder, Isabelle C ^b   Walfridsson, Håkan ^c   Kulakowski, Piotr ^d   Rónaszéki, Aladár ^e   Dedek, Vratislav ^f   Malm, Anders ^g   Almgren, Olle ^g  

^a MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^d GROCHOWSKI HOSPITAL   (Poland)

^e Peterfi Hospital   (Hungary)

^f Hospital Ústí nad Orlicí   (Czech Republic)

^g ASTRAZENECA R AND D   (Sweden)

Author keywords

Antiarrhythmic drug; Atrial fibrillation; Atrial flutter; AZD7009; Proarrhythmia; Sinus rhythm

Indexed keywords

ACENOCOUMAROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIARRHYTHMIC AGENT; ANTIDIABETIC AGENT; AZD 7009; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FUROSEMIDE; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVOTHYROXINE; METOPROLOL; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; AGED; ANTIARRHYTHMIC ACTIVITY; ARTICLE; BRADYCARDIA; CARDIOVERSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART FAILURE; HEART PROARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; HYPOTENSION; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SINUS BRADYCARDIA; SINUS RHYTHM; STEADY STATE; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; TIME; TORSADE DES POINTES;

AGED; ATRIAL FIBRILLATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART RATE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; ORGANIC CHEMICALS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 33750388727     PISSN: 15475271     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hrthm.2006.06.035     Document Type: Article

References (25)

1. Lip G.Y., Tean K.N., and Dunn F.G. Treatment of atrial fibrillation in a district general hospital. Br Heart J 71 (1994) 92-95
2. Benjamin E.J., Wolf P.A., D'Agostino R.B., Silbershatz H., Kannel W.B., and Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation 98 (1998) 946-952
3. Dorian P., Jung W., Newman D., Paquette M., Wood K., Ayers G.M., Camm J., Akhtar M., and Luderitz B. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol 36 (2000) 1303-1309
4. Luderitz B., and Jung W. Quality of life in patients with atrial fibrillation. Arch Intern Med 160 (2000) 1749-1757
5. Go A.S., Hylek E.M., Phillips K.A., Chang Y., Henault L.E., Selby J.V., and Singer D.E. Prevalence of diagnosed atrial fibrillation in adults. National implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. Jama 285 (2001) 2370-2375
6. Pappone C., Rosanio S., Augello G., Gallus G., Vicedomini G., Mazzone P., Gulletta S., Gugliotta F., Pappone A., Santinelli V., Tortoriello V., Sala S., Zangrillo A., Crescenzi G., Benussi S., and Alfieri O. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol 42 (2003) 185-197
7. Hagens V.E., Ranchor A.V., Van Sonderen E., Bosker H.A., Kamp O., Tijssen J.G., Kingma J.H., Crijns H.J., Van Gelder I.C., and RACE Study Group. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol 43 (2004) 241-247
8. Fuster V., Ryden L.E., Asinger R.W., Cannom D.S., Crijns H.J., Frye R.L., Halperin J.L., Kay G.N., Klein W.W., Levy S., McNamara R.L., Prystowsky E.N., Wann L.S., and Wyse D.G. American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients With Atrial Fibrillation); North American Society of Pacing and Electrophysiology. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. Circulation 104 (2001) 2118-2150
9. Kobayashi Y., Atarashi H., Ino T., Kuruma A., Nomura A., Saitoh H., and Hayakawa H. Clinical and electrophysiologic effects of dofetilide in patients with supraventricular tachyarrhythmias. J Cardiovasc Pharmacol 30 (1997) 367-373
10. Oshikawa N., Watanabe I., Masaki R., Shindo A., Kojima T., Saito S., Ozawa Y., and Kanmatsuse K. Frequency-dependent electrophysiological effect of ibutilide on human atrium and ventricle. J Interv Card Electrophysiol 5 (2001) 81-87
11. K blocker almokalant exhibits class III-specific effects on the repolarization and refractoriness of the human heart: a study of healthy volunteers using right ventricular monophasic action potential recordings. J Cardiovasc Pharmacol 26 (1995) 530-540
12. Fenichel R.R., Malik M., Antzelevitch C., Sanguinetti M., Roden D.M., Priori S.G., Ruskin J.N., Lipicky R.J., Cantilena L.R., and Independent Academic Task Force. Drug-induced torsades de pointes and implications for drug development. J Cardiovasc Electrophysiol 15 (2004) 475-495
13. Duker G., Björkman J.A., Linhardt G., and Carlsson L. AZD7009-a new atrial antifibrillatory compound that markedly delays atrial refractoriness in the anaesthetised dog. Heart Rhythm 1 (2004) S159
14. Goldstein R.N., Khrestian C., Carlsson L., and Waldo A.L. AZD7009: a new antiarrhythmic drug with predominant effects on the atria effectively terminates and prevents reinduction of atrial fibrillation and flutter in the sterile pericarditis model. J Cardiovasc Electrophysiol 15 (2004) 1444-1450
15. Persson F., Carlsson L., Duker G., and Jacobson I. Blocking characteristics of hERG, hNav1.5 and hKvLQT1/hminK after administration of the novel antiarrhythmic compound AZD7009. J Cardiovasc Electrophysiol 16 (2005) 329-341
16. Edvardsson N., Walfridsson H., and Aass H. Predominant effects on atrial versus ventricular refractoriness in man by the novel antiarrhythmic agent AZD7009. Eur Heart J 26 Suppl 1 (2005) 506
17. Guidance for industry: E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs (2005), US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Rockville, MD. http://www.fda.gov/cder/guidance/6922fnl.htm October. Available at: http://www.fda.gov/cder/guidance/6922fnl.htm. Accessed February 16, 2006.
18. Ellenbogen K.A., Stambler B.S., Wood M.A., Sager P.T., Wesley Jr. R.C., Meissner M.C., Zoble R.G., Wakefield L.K., Perry K.T., and Vanderlugt J.T. Efficacy of intravenous ibutilide for rapid termination of atrial fibrillation and atrial flutter: a dose-response study. J Am Coll Cardiol 28 (1996) 130-136
19. Reisinger J., Gatterer E., Heinze G., Wiesinger K., Zeindlhofer E., Gattermeier M., Poelzl G., Kratzer H., Ebner A., Hohenwallner W., Lenz K., Slany J., and Kuhn P. Prospective comparison of flecainide versus sotalol for immediate cardioversion of atrial fibrillation. Am J Cardiol 81 (1998) 1450-1454
20. Vardas P.E., Kochiadakis G.E., Igoumenidis N.E., Tsatsakis A.M., Simantirakis E.N., and Chlouverakis G.I. Amiodarone as a first-choice drug for restoring sinus rhythm in patients with atrial fibrillation: a randomized, controlled study. Chest 117 (2000) 1538-1545
21. ACT I investigators, Pratt C., Wyse D.G., Toft E., Torp-Pedersen C., and Juul-Moller S. Efficacy and safety of RSD1235 in the treatment of recent onset atrial fibrillation in ACT I (Atrial arrhythmia Conversion Trial I), a phase III, randomised, placebo-controlled, multi-center trial. Eur Heart J 26 Abstract Suppl (2005) 506
22. Wu Y., Carlsson L., Liu T., Kowey P., and Yan G.-X. Assessment of the proarrhythmic potential of the novel antiarrhythmic agent AZD7009 and dofetilide in experimental models of torsades de pointes. J Cardiovasc Electrophysiol 8 (2005) 898-904
23. Carlsson L., Drews L., Duker G., and Schiller-Linhardt G. Attenuation of proarrhythmias related to delayed repolarization by low-dose lidocaine in the anesthetized rabbit. J Pharmacol Exp Ther 267 (1993) 1076-1080
24. Shimizu W., and Antzelevitch C. Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation 96 (1997) 2038-2047
25. Antzelevitch C. Tpeak-Tend interval as an index of transmural dispersion of repolarization. Eur J Clin Invest 31 (2001) 555-557